Skip to main content
OpenTrials
Completed

NCT Number: NCT01482377

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

This dose-escalating study consists of 3 parts (A, B and C) and will evaluate the safety, pharmacokinetics and efficacy of RO5479599, alone or in combination with cetuximab or erlotinib, in participants with metastatic and/or locally advanced malignant HER3-positive solid tumors. Cohorts of participants will receive escalating doses of intravenous RO5479599 as monotherapy (Part A) or in combination with cetuximab (in Part B) or with erlotinib (in Part C) followed by an extension phase for each part.

In an imaging substudy, participants will receive one or two doses of zirconium-89-labeled RO5479599 (89ZrRO5479599) in addition to unlabeled RO5479599 to evaluate the in vivo biodistribution and organ pharmacokinetics of RO5479599.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Rigshospitalet, Onkologisk Klinik, København Ø, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All Parts (A, B and C)

  • European Cooperative Oncology Group (ECOG) performance status 0-2
  • Histologically confirmed metastatic and/or locally advanced malignant HER3-expressing solid tumors of epithelial origin
  • Availability of tissue and willingness to perform fresh pretreatment biopsies
  • Participants for whom no standard therapy exists
  • All acute toxic effects of any prior radiotherapy, chemotherapy or surgical procedure must have resolved to Grade less than or equal to (</= 1), except for alopecia and Grade 2 peripheral neuropathy
  • Adequate hematological, renal and liver function
  • Participants with Gilbert's syndrome will be eligible for the study

Part B extension cohort: In addition to the above inclusion criteria, participants will be eligible if they have metastatic and/or locally advanced non-small cell lung cancer or squamous cell carcinoma of the head and neck or colorectal cancer (wild type with positive epidermal growth factor receptor [EGFR] expression)

Part C extension cohort: In addition to the above inclusion criteria, participants will be eligible only if they have metastatic and/or locally advanced squamous non-small cell lung cancer

Exclusion criteria

  • Known or clinically suspected central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases. History or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days
  • Evidence of significant uncontrolled concomitant diseases or disorders
  • Active or uncontrolled infections
  • Known Human immuno deficiency virus (HIV) infection
  • Therapy with antibody or immunotherapy concurrently or within 14 days prior to first dose of study drug
  • Regular immunosuppressive therapy
  • Concurrent high dose of systemic corticosteroids (greater than (>) 20 milligrams per day [mg/day] dexamethasone or equivalent for > 7 consecutive days)

Treatment and study plan

RO5479599

Drug

RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).

Cetuximab

Drug

Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions.

Erlotinib

Drug

Erlotinib, at a dose of 150 mg will be administered.

zirconium-89-labeled RO5479599

Drug

Single dose of radiolabeled drug will be administered.

Primary outcomes

  1. Percentage of Participants With Adverse Events

    Time frame: Baseline up to 28 days after last dose (approximately 48 months)

  2. Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of RO5479599

    Time frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

  3. Number of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

  4. Standardized Uptake Value (SUV) of 89ZrRO5479599 Determined by Positron Emission Tomography (PET) Scan Over Regions of Interest (ROI)

    Time frame: From baseline to Day 8

Secondary outcomes

  1. Percentage Change From Baseline in Standardized Uptake Value (SUV) of 89ZrRO5479599 at Pharmacodynamic (PD) active dose as Determined by PET Scan

    Time frame: From baseline to Day 22

  2. Part A: Recommended Phase II Dose (RPTD) of RO5479599 in Monotherapy

    Time frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

  3. Part B: Recommended Phase II Dose of RO5479599 in Combination With Cetuximab

    Time frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

  4. Part C: Recommended Phase II Dose of RO5479599 in Combination With Erlotinib

    Time frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days

  5. Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for two weekly schedule [Q2W] and every ninth week for three weekly schedule [Q3W] up to approximately 48 months)

  6. Percentage of Participants With Disease Control According to RECIST version 1.1

    Time frame: From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months)

  7. Duration of Response According to RECIST version 1.1

    Time frame: From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months)

  8. Progression Free Survival According to RECIST version 1.1

    Time frame: From screening to disease progression, death, withdrawal, or end of study (assessed at screening, then every eighth week for Q2W and every ninth week for Q3W up to approximately 48 months)

  9. Maximum Serum Concentration (Cmax) of RO5479599 for Q2W Schedule

    Time frame: Pre-infusion (PrI, 0 hours [hr]) & end of infusion (EOI, 1.5 hr) on each 2-week cycle (Cy); 2, 5 hr post-infusion (PoI) on Cy1 Day 1 (D1), Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  10. Cmax of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  11. Trough Serum Concentration (Cmin) for Q2W Schedule

    Time frame: PreI (0 hr) on D1 of each cycle from Cy2 (up to 48 months overall) (Cycle length = 14 days)

  12. Cmin for Q3W Schedule

    Time frame: PreI (0 hr) on D1 of each cycle from Cy2 (up to 48 months overall) (Cycle length = 21 days)

  13. Time to Reach Maximum Serum Concentration (Tmax) of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  14. Tmax of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  15. Area Under the Plasma Concentration-Time Curve (AUC) of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  16. AUC of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  17. Clearance (CL) of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  18. CL of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  19. Volume of Distribution (Vd) of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  20. Vd of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  21. Accumulation Ratio of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  22. Accumulation Ratio of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  23. Terminal Elimination Half-Life (t1/2) of RO5479599 for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  24. t1/2 of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  25. Serum Concentration of RO5479599 at Time of Tumor Progression (Cprog) for Q2W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 2-week Cy; 2, 5 hr PoI on Cy1 D1, Cy1 Days 2, 3, 5, 8, 12; 2 hr PoI on Cy4D1; Cy4 Days 2, 3, 5, 8; Cy8 Days 2, 5, 8 (up to 48 months overall)

  26. Cprog of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) & EOI (1.5 hr) on each 3-week Cy; 3 hr PoI on Cy1 D1, Cy1 Days 2, 4, 8, 12, 14, 19, 21; 3 hr PoI on Cy4 D1, Cy8 D1; Days 2, 4, 8, 12, 14, 19, 21 on Cy4 and Cy8 (up to 48 months overall)

  27. Serum Concentration of RO5479599 at the Time of Tumor Response for Q2W Schedule

    Time frame: At the time of objective response (up to 48 months)

  28. Serum Concentration of RO5479599 at the Time of Tumor Response for Q3W Schedule

    Time frame: At the time of objective response (up to 48 months)

  29. Serum Concentration of RO5479599 at the Time of DLT for Q2W Schedule

    Time frame: At the time of DLT (up to 28 days)

  30. Serum Concentration of RO5479599 at the Time of DLT for Q3W Schedule

    Time frame: At the time of DLT (up to 28 days)

  31. Serum Concentration of RO5479599 at the Time of Tumor and Skin Biopsy (Cb) for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 and on Cy1 Day 14 (Cycle length = 14 days)

  32. Cb of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 and on Cy1 Day 21 (Cycle length = 21 days)

  33. Serum Concentration of RO5479599 at the Time of PET Scan (Cpet) for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1, Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  34. Cpet of RO5479599 for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1, Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  35. Serum Concentration of RO5479599 at Time of Infusion-Related Reactions (IRRs) for Q2W Schedule

    Time frame: At the time of IRR (up to 48 months)

  36. Serum Concentration of RO5479599 at Time of IRRs for Q3W Schedule

    Time frame: At the time of IRR (up to 48 months)

  37. Change from Baseline in T Lymphocytes Cell Count for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  38. Change from Baseline in T lymphocytes Cell Count for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  39. Change from Baseline in Natural Killer Cell Count for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  40. Change from Baseline in Natural Killer Cell Count for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  41. Change from Baseline in Macrophages Cell Count for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  42. Change from Baseline in Macrophages Cell Count for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  43. Change from Baseline in Cytokines Level for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  44. Change from Baseline in Cytokines Level for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  45. Change from Baseline in HER3 Expression for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  46. Change from Baseline in HER3 Expression for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

  47. Change from Baseline in Phosphorylated HER3 Expression for Q2W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 14, and Cy4 Day 14 (Cycle length = 14 days)

  48. Change from Baseline in Phosphorylated HER3 Expression for Q3W Schedule

    Time frame: PrI (0 hr) on Cy1D1 (Baseline), Cy1 Day 21, and Cy3 Day 21 (Cycle length = 21 days)

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

Phase Ia/Ib, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, A Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotinib (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors of Epithelial Cell Origin

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Nov 30, 2011
Registry last updated
Jan 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.